FDA Approves a Brand Name Change for Antidepressant Brintellix to Trintellix

 In FDA

Brintellix (vortioxetine) is a relatively new serotonergic antidepressant, approved to treat major depressive disorder in September 2013. In recent FDA MedWatch news, there were numerous reports of name confusion between Brintellix and the antiplatelet drug, Brillinta, not only among the consumers, but also among healthcare professionals. On May 2, 2016, the FDA approved a brand name change from Brintellix to Trintellix in order to decrease the risk of prescribing and dispensing errors. As of June 2016, Brintellix will be marketed as Trintellix and will also have a new National Drug Code (NDC).

Although there is a new brand name and NDC, the formulation, indication and dosages of 5 mg, 10 mg and 20 mg tablets will remain the same. Pharmacies, insurance carriers and healthcare providers are advised to update their medication-related electronic systems with the new brand name. During the transition to the new brand name, healthcare providers are also advised to carefully check to make sure they have prescribed or dispensed the correct medication and educate patients about the name change.

The FDA also encourages patients and healthcare professionals to report medication errors, name confusion, adverse events or side effects related to the use of vortioxetine (Brintellix/Trintellix) and Brillinta by calling FDA’s MedWatch Program at 800-332-1088 or visit the FDA’s MedWatch website.

Reference:

  1. FDA Drug Safety Communication: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brillinta (ticagrelor). (2016, May 2).

Leave a Comment